Cargando…

Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in a young transgender woman: A case report

INTRODUCTION: Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare T-cell lymphoma occurring after breast implant procedures. As gender confirmation therapy (GCT) in male-to-female transgender (FT), up to 60–70 % of patients require breast augmentation and are at risk for BI...

Descripción completa

Detalles Bibliográficos
Autores principales: Materazzo, Marco, Vanni, Gianluca, Rho, Maurizio, Buonomo, Chiara, Morra, Emanuela, Mori, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434022/
https://www.ncbi.nlm.nih.gov/pubmed/36030763
http://dx.doi.org/10.1016/j.ijscr.2022.107520
_version_ 1784780770802401280
author Materazzo, Marco
Vanni, Gianluca
Rho, Maurizio
Buonomo, Chiara
Morra, Emanuela
Mori, Stefano
author_facet Materazzo, Marco
Vanni, Gianluca
Rho, Maurizio
Buonomo, Chiara
Morra, Emanuela
Mori, Stefano
author_sort Materazzo, Marco
collection PubMed
description INTRODUCTION: Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare T-cell lymphoma occurring after breast implant procedures. As gender confirmation therapy (GCT) in male-to-female transgender (FT), up to 60–70 % of patients require breast augmentation and are at risk for BIA-ALCL. Hence, we report the youngest BIA-ALCL case in the Italian population and the first early-stage BIA-ALCL occurred in FT patients. CASE PRESENTATION: A 27-years-old FT was admitted to outpatients' clinics due to swollen left breast. The patient underwent GCT with a macrotextured implant four years before. Clinical examination revealed swollen left breast. Ultrasound and magnetic resonance imaging confirmed left breast periprosthetic effusion. Positron emission tomography-computed tomography scan did not reveal any focal pathological uptake. Fine needle aspiration cytology confirmed BIA-ALCL suspect. The patient underwent bilateral en bloc breast implant removal and periprosthetic capsulectomy. Due to the early stage, adjuvant chemotherapy was omitted. Postoperative follow-up was unremarkable. CLINICAL DISCUSSION: BIA-ALCL is a rare, emergent clinical concern after breast implant surgery. GCT leads to improved body satisfaction and quality of life in FT individuals. As for non-trans patients undergoing breast reconstruction or breast augmentation, this clinical case once again demonstrates that FT patients undergoing breast implant surgery are at risk of BIA-ALCL. CONCLUSION: Physicians should promote awareness among patients' GCT and tailored postoperative follow-up.
format Online
Article
Text
id pubmed-9434022
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94340222022-09-02 Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in a young transgender woman: A case report Materazzo, Marco Vanni, Gianluca Rho, Maurizio Buonomo, Chiara Morra, Emanuela Mori, Stefano Int J Surg Case Rep Case Report INTRODUCTION: Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) is a rare T-cell lymphoma occurring after breast implant procedures. As gender confirmation therapy (GCT) in male-to-female transgender (FT), up to 60–70 % of patients require breast augmentation and are at risk for BIA-ALCL. Hence, we report the youngest BIA-ALCL case in the Italian population and the first early-stage BIA-ALCL occurred in FT patients. CASE PRESENTATION: A 27-years-old FT was admitted to outpatients' clinics due to swollen left breast. The patient underwent GCT with a macrotextured implant four years before. Clinical examination revealed swollen left breast. Ultrasound and magnetic resonance imaging confirmed left breast periprosthetic effusion. Positron emission tomography-computed tomography scan did not reveal any focal pathological uptake. Fine needle aspiration cytology confirmed BIA-ALCL suspect. The patient underwent bilateral en bloc breast implant removal and periprosthetic capsulectomy. Due to the early stage, adjuvant chemotherapy was omitted. Postoperative follow-up was unremarkable. CLINICAL DISCUSSION: BIA-ALCL is a rare, emergent clinical concern after breast implant surgery. GCT leads to improved body satisfaction and quality of life in FT individuals. As for non-trans patients undergoing breast reconstruction or breast augmentation, this clinical case once again demonstrates that FT patients undergoing breast implant surgery are at risk of BIA-ALCL. CONCLUSION: Physicians should promote awareness among patients' GCT and tailored postoperative follow-up. Elsevier 2022-08-15 /pmc/articles/PMC9434022/ /pubmed/36030763 http://dx.doi.org/10.1016/j.ijscr.2022.107520 Text en © 2022 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Materazzo, Marco
Vanni, Gianluca
Rho, Maurizio
Buonomo, Chiara
Morra, Emanuela
Mori, Stefano
Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in a young transgender woman: A case report
title Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in a young transgender woman: A case report
title_full Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in a young transgender woman: A case report
title_fullStr Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in a young transgender woman: A case report
title_full_unstemmed Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in a young transgender woman: A case report
title_short Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) in a young transgender woman: A case report
title_sort breast implant-associated anaplastic large cell lymphoma (bia-alcl) in a young transgender woman: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434022/
https://www.ncbi.nlm.nih.gov/pubmed/36030763
http://dx.doi.org/10.1016/j.ijscr.2022.107520
work_keys_str_mv AT materazzomarco breastimplantassociatedanaplasticlargecelllymphomabiaalclinayoungtransgenderwomanacasereport
AT vannigianluca breastimplantassociatedanaplasticlargecelllymphomabiaalclinayoungtransgenderwomanacasereport
AT rhomaurizio breastimplantassociatedanaplasticlargecelllymphomabiaalclinayoungtransgenderwomanacasereport
AT buonomochiara breastimplantassociatedanaplasticlargecelllymphomabiaalclinayoungtransgenderwomanacasereport
AT morraemanuela breastimplantassociatedanaplasticlargecelllymphomabiaalclinayoungtransgenderwomanacasereport
AT moristefano breastimplantassociatedanaplasticlargecelllymphomabiaalclinayoungtransgenderwomanacasereport